05/03/2023 at 6:30 pm
Unmitigated early-life seizures are associated with life-long physical, cognitive, and behavioral impairments. Early and accurate diagnosis of infantile and childhood seizure disorders is a crucial first step in identifying effective treatment that can mitigate the impacts of seizures on the developing brain. Unfortunately, diagnosis and subtype classification of early-onset epilepsies is frequently delayed until long after the seizures have begun. Clinicians need to confidently differentiate Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), and tuberous sclerosis complex (TSC), as causes of seizure to form efficient strategies to treat these notoriously resistant conditions. Further, the diagnostic journey and disease management of children with epilepsy conditions is associated with significant quality of life (QoL) impacts on both the patient and family.
Please join expert faculty in this live CMEO webcast as they discuss topics including early diagnosis, patient/caregiver QoL, team-based care, the role of pharmaceutical cannabinoid (CBD) in treatment, and regulatory guidelines. Through this discussion learners will become acquainted with improved tactics to diagnose and treat early-life seizures.
At the end of this CME/CE activity, participants should be able to:
Utilize validated assessment tools to achieve early and accurate differential diagnosis of rare childhood seizure disorders, including LGS, DS, and TSC.
Incorporate patient/caregiver QoL assessment and treatment goals into team-based management of pediatric seizure disorders.
Examine the role of pharmaceutical CBD in antiepileptic therapy, including outcomes data, formulation/dosing considerations, augmentation strategies, and regulatory requirements.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals, Inc.
Physicians, nurse practitioners, PAs, nurses, and pharmacists specializing in primary care or emergency medicine.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Wirrell reports the following financial relationships: Advisory Board: Biohaven and Eisai Inc. Consultant: DSMB for Acadia Pharmaceuticals Inc.; Amicus Therapeutics, Inc.; GRIN Therapeutics; and Neurocrine Biosciences, Inc. Grants: Dravet Syndrome Foundation Research Support: (all payments made to Mayo) Marinus Pharmaceuticals, Inc.; UCB, Inc.; and Zogenix, Inc.
Dr. Reddy reports no financial relationships to disclose.
The following peer reviewer and CME Outfitters staff have no financial relationships:
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (peer reviewer)
Evan Luberger (planning committee)
Kellie Busby, PharmD (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sandra Caballero, PharmD (planning committee)
Sharon Tordoff (planning committee)
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at (877) CME-PROS or (877) 263-7767.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-23-027-L01-P